Age: 26.0
Sex: F
Vaccine: FLUX, PPV
Symptoms: Anaphylactic reaction, Dyspnoea, Heart rate increased, Laboratory test, Nasal congestion
Clinical narrative: This case was reported in a literature article and described the occurrence of anaphylaxis in a 26-year-old female subject who received Flu seasonal TIV Dresden. This case refers to patient 2 in the literature article. Co-suspect products included 23-valent pneumococcal polysaccharide vaccine. Concurrent medical conditions included asthma. On an unknown date, an unknown time after receiving Flu seasonal TIV Dresden, the subject developed anaphylaxis. Serious criteria included GSK medically significant and life threatening. Additional event(s) included wheezing, shortness of breath, nasal congestion and nausea. The subject was treated with nebulizer (name unknown). The outcome of anaphylaxis was recovered/resolved. The outcome(s) of the additional event(s) included wheezing (recovered/resolved), shortness of breath (recovered/resolved), nasal congestion (recovered/resolved) and nausea (recovered/resolved). The investigator considered that there was a reasonable possibility that the anaphylaxis, wheezing, shortness of breath, nasal congestion and nausea may have been caused by Flu seasonal TIV Dresden. Relevant Tests: Lab test performed on unknown date Diagnostic results (unless otherwise stated, normal values were not provided): On an unknown date, heart rate result was increased. Additional information was provided: This case was reported in a literature article and it described the occurrence of a vaccine-triggered anaphylaxis in a 26-year-old female patient who had received an unspecified trivalent influenza vaccine (manufacturer unknown) and an unspecified 23-valent pneumococcal polysaccharide vaccine (manufacturer unknown). The patient was a female. The subject's medical history included atopic disease with asthma. No further information on the patient's concurrent medical conditions, medical or family history, or concomitant medication was provided. On an unspecified date, between the 1st of January of 2009 and the 31st of December 2011, the patient received an unspecified dose of an unspecified trivalent influenza vaccine and an unspecified 23-valent pneumococcal polysaccharide vaccine (dosages unknown; administration routes and sites unspecified; batch numbers not provided). On an unspecified date, an unknown period after the vaccination, the patient developed bilateral wheeze, shortness of breath, heart rate increased, nasal congestion and nausea. This was classified as anaphylaxis by the emergency department doctor. According to the authors the case was considered as Brighton level 2 and setting of initial evaluation was the emergency department. The patient was treated by nebulizer. At the time of reporting the outcome of the events was recovered. This event was classified as vaccine related according to the authors. The authors concluded that "Anaphylaxis after vaccination is rare in all age groups. Despite its rarity, anaphylaxis is a potentially life-threatening medical emergency that vaccine providers need to be prepared to treat. This case is 1 of the 28 valid cases reported in the same literature article.